Patt Marianne, Solbach Christoph, Wüllner U, Blocher A, Stahlschmidt Anke, Gündisch Daniela, Kovar K-A, Machulla Hans-Jürgen
Department of Nuclear Medicine, University Hospital, University of Leipzig, Germany.
J Pharm Pharm Sci. 2007;10(2):312s-320s.
The purpose of this study was a) to present a facilitated method for the preparation and workup of [11C]d-threo-methylphenidate ([11C]d-threo-MP) (a ligand that was shown to bind selectively to the presynaptic dopaminergic transporters) from [11C]methyliodide ([11C]CH3I), b) to demonstrate that the ligand can as well be produced by an alternative labeling method employing [11C]diazomethane as the labeling agent and c) to present biodistribution data for this tracer obtained in rats.
11C-labeling with [11C]CH3I was performed using either [d-threo-1-(2-nitrophenylsulfanyl)piperidin-2-yl]phenyl-acetic acid (d-threo-N-NPS-ritalinic acid) under addition of sodium hydroxide as base or the previously prepared sodium salt of d-threo-N-NPS-ritalinic acid. The two approaches were compared with regard to radiochemical yield and purification procedures needed in order to obtain a sufficiently pure tracer solution for human use. For the alternative reaction pathway using [11C]diazo-methane as the labeling agent the reaction was performed with d-threo-N-NPS-ritalinic acid. The biodistribution of [11C]d-threo-MP was determined in rats at 5, 10 and 30 min post injection of the tracer.
The application of the sodium salt of d-threo-N-NPS-ritalinic acid as precursor resulted in higher radiochemical yields than the use of the free acid under basic conditions, the yields were 20 +/- 8% and 6 +/- 3%, respectively for the final isolated product (based on [11C]CH3I starting activity). The alternative labeling approach by means of [11C]diazomethane as the labeling agent was demonstrated to give radiochemical yields of 76 +/- 8% (based on [11C]diazomethane starting activity, determined by HPLC analysis of the crude reaction mixture before final work-up) within shorter process times. Based on [11C]methane starting activity both approaches result in similar yields (17% and 15%, respectively) Biodistribution studies in rats revealed a low blood activity (0.09% injected dose/g (% ID/g)) at 5 min post injection (p.i.), as well as a relatively high liver uptake (15.9% ID at 30 min) compared to a lower kidney uptake (3.2% ID at 30 min). Brain uptake was 0.9% ID/g already 5 and 10 min p.i..
The application of the sodium salt of d-threo-N-NPS-ritalinic acid as precursor for the radiosynthesis of [11C]d-threo-MP reduces the amount of [11C]methanol formed from the reaction of [11C]CH3I with sodium hydroxide, that is added to generate the carboxylic anion of d-threo-N-NPS-ritalinic acid needed for labeling with [11C]CH3I. The purification process could be simplified (omission of one solid phase extraction step), resulting in an easily automated process for the production of the tracer. The preparation of [11C]d-threo-MP by means of [11C]diazomethane as the labeling agent appears to be an interesting alternative to the [11C]CH3I methods because of shorter overall process times and high labeling yields. Biodistribution data show a rapid extraction of the tracer from the blood pool. Tracer excretion seems to take place predominantly via the hepatic pathway since liver uptake at 30 min was considerably higher than kidney uptake. [11C]d-threo-MP exhibits a rapid and sufficiently high brain uptake in rats.
本研究的目的是:a)介绍一种简便的方法,用于从[¹¹C]碘甲烷([¹¹C]CH₃I)制备和后处理[¹¹C]d-苏式-甲基苯丙胺([¹¹C]d-threo-MP)(一种已证明能选择性结合突触前多巴胺能转运体的配体);b)证明该配体也可以通过采用[¹¹C]重氮甲烷作为标记剂的替代标记方法来制备;c)展示在大鼠中获得的该示踪剂的生物分布数据。
使用[¹¹C]CH₃I进行¹¹C标记时,在加入氢氧化钠作为碱的条件下,使用[d-苏式-1-(2-硝基苯基硫烷基)哌啶-2-基]苯基乙酸(d-苏式-N-NPS-利他林酸),或者使用预先制备的d-苏式-N-NPS-利他林酸钠盐。比较了这两种方法的放射化学产率以及为获得足够纯的供人体使用的示踪剂溶液所需的纯化程序。对于使用[¹¹C]重氮甲烷作为标记剂的替代反应途径,反应使用d-苏式-N-NPS-利他林酸进行。在注射示踪剂后5、10和30分钟,测定大鼠体内[¹¹C]d-threo-MP的生物分布。
使用d-苏式-N-NPS-利他林酸钠盐作为前体,放射化学产率高于在碱性条件下使用游离酸,最终分离产物的产率分别为20±8%和6±3%(基于[¹¹C]CH₃I起始活性)。以[¹¹C]重氮甲烷作为标记剂的替代标记方法在更短的处理时间内,放射化学产率达到76±8%(基于[¹¹C]重氮甲烷起始活性,通过对最终后处理前的粗反应混合物进行HPLC分析确定)。基于[¹¹C]甲烷起始活性,两种方法的产率相似(分别为17%和15%)。大鼠体内的生物分布研究显示,注射后5分钟(p.i.)时血液活性较低(0.09%注射剂量/克(% ID/g)),与较低的肾脏摄取(30分钟时为3.2% ID)相比,肝脏摄取相对较高(30分钟时为15.9% ID)。注射后5分钟和10分钟时,脑摄取量已达0.9% ID/g。
使用d-苏式-N-NPS-利他林酸钠盐作为前体进行[¹¹C]d-threo-MP的放射性合成,减少了[¹¹C]CH₃I与氢氧化钠反应生成的[¹¹C]甲醇的量,加入氢氧化钠是为了生成用[¹¹C]CH₃I标记所需的d-苏式-N-NPS-利他林酸的羧酸阴离子。纯化过程可以简化(省略一个固相萃取步骤),从而实现示踪剂生产的易于自动化的过程。以[¹¹C]重氮甲烷作为标记剂制备[¹¹C]d-threo-MP似乎是[¹¹C]CH₃I方法的一个有趣替代方案,因为总体处理时间更短且标记产率高。生物分布数据表明示踪剂能迅速从血池清除。示踪剂的排泄似乎主要通过肝脏途径进行,因为30分钟时肝脏摄取量远高于肾脏摄取量。[¹¹C]d-threo-MP在大鼠体内表现出快速且足够高的脑摄取。